Polaryx Therapeutics, Inc. — Investor Relations & Filings

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). The company utilizes a patient-first approach, advancing a diversified pipeline of small molecule and gene therapy treatments. Key therapeutic candidates, such as PLX-200 and PLX-300, target multiple LSD indications including Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2), Juvenile Neuronal Ceroid Lipofuscinosis (CLN3), Krabbe Disease, Sandhoff Disease, Niemann-Pick Type A/B, and GM2 Gangliosidoses. Polaryx emphasizes patient-friendly administration methods, including oral and intranasal formulations, and has secured various FDA designations, such as Orphan Drug, Rare Pediatric Disease, and Fast Track, for its programs.